MXPA02003463A - Complejos de galio de 3-hidroxi-4-pironas para tratar la infeccion por procariontes intracelulares, virus de adn y retrovirus. - Google Patents

Complejos de galio de 3-hidroxi-4-pironas para tratar la infeccion por procariontes intracelulares, virus de adn y retrovirus.

Info

Publication number
MXPA02003463A
MXPA02003463A MXPA02003463A MXPA02003463A MXPA02003463A MX PA02003463 A MXPA02003463 A MX PA02003463A MX PA02003463 A MXPA02003463 A MX PA02003463A MX PA02003463 A MXPA02003463 A MX PA02003463A MX PA02003463 A MXPA02003463 A MX PA02003463A
Authority
MX
Mexico
Prior art keywords
hiv
methods
infection
obligate intracellular
treating
Prior art date
Application number
MXPA02003463A
Other languages
English (en)
Inventor
R Bernstein Lawrence
Original Assignee
R Bernstein Lawrence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Bernstein Lawrence filed Critical R Bernstein Lawrence
Publication of MXPA02003463A publication Critical patent/MXPA02003463A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen metodos para tratar o evitar infecciones mediante procariontes intracelulares obligados, incluyendo micoplasma, rickettsia y clamidia, retrovirus, y virus de ADN, incluyendo herpes virus, papiloma virus, adenovirus y virus de hepatitis B; se hace enfasis en proveer metodos para el tratamiento de enfermedad por HIV; ademas de proveer metodos para tratar infeccion de HIV en si, se proveen metodos para tratar a un paciente HIV que tiene una coinfeccion por otro retrovirus, un procarionte intracelular obligado, o un virus de ADN; los metodos implican la administracion complejos 3:1de 3- hidroxi-4-ironas con galio, por ejemplo, maltolato de galio; las terapias que incorporan maltolato de galio en combinacion con agentes que se utilizan contra procarionte intracelular obligado, retrovirus y patogenos de virus de ADN tambien se proveen, como son terapias de multicombinacion disenadas para tratar coinfeccion mediante un procarionte intracelular obligado, retrovirus o virus de ADN en un individuo infectado por HIV; estas terapias de combinacion multiple se apoyan en la capacidad de maltolato de galio para complementar los regimenes de medicacion antiviral contra HIV y otros patogenos tales como infecciones por herpes virus, incluyendo sarcoma de Kaposi, retinitis CMV y ceguera, y linfomas, en pacientes inmunocomprometidos por infeccion de HIV.
MXPA02003463A 1999-10-04 2000-10-04 Complejos de galio de 3-hidroxi-4-pironas para tratar la infeccion por procariontes intracelulares, virus de adn y retrovirus. MXPA02003463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15746099P 1999-10-04 1999-10-04
PCT/US2000/028174 WO2001024799A1 (en) 1999-10-04 2000-10-04 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses

Publications (1)

Publication Number Publication Date
MXPA02003463A true MXPA02003463A (es) 2004-09-10

Family

ID=22563820

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003463A MXPA02003463A (es) 1999-10-04 2000-10-04 Complejos de galio de 3-hidroxi-4-pironas para tratar la infeccion por procariontes intracelulares, virus de adn y retrovirus.

Country Status (10)

Country Link
US (2) US20030083308A1 (es)
EP (1) EP1218011B1 (es)
JP (1) JP2003510362A (es)
KR (1) KR20020041451A (es)
AU (1) AU775459B2 (es)
CA (1) CA2386325C (es)
DE (1) DE60032915T2 (es)
ES (1) ES2280259T3 (es)
MX (1) MXPA02003463A (es)
WO (1) WO2001024799A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071425A2 (en) * 2003-02-06 2004-08-26 Bioresponse, Llc The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
WO2005058331A1 (en) * 2003-12-17 2005-06-30 Titan Pharmaceuticals, Inc. Use of gallium to treat inflammatory arthritis
DK1781265T3 (da) * 2004-08-25 2010-08-02 Essentialis Inc Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
WO2006083458A2 (en) 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
CN101484178A (zh) 2005-11-01 2009-07-15 赛德罗米克斯有限责任公司 使用镓化合物的口部和表面微生物的生长控制
CN101300033A (zh) * 2005-11-07 2008-11-05 泰坦医药品公司 用镓对不良肝脏病症的治疗和预防
EP1978976A2 (en) * 2006-01-30 2008-10-15 Titan Pharmaceuticals, Inc. Use of gallium to treat biofilm-associated infectons
US8168214B2 (en) 2006-11-09 2012-05-01 Bernstein Lawrence R Local administration of gallium compositions to treat pain
US20080175922A1 (en) * 2007-01-23 2008-07-24 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
WO2009009171A2 (en) * 2007-04-02 2009-01-15 Sideromics, Llc Methods for preventing or treating infectious diseases using gallium compounds
WO2009111681A2 (en) * 2008-03-07 2009-09-11 Lawrence Bernstein Gallium compounds and methods of use to treat inflammatory bowel disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717653A (en) * 1981-09-25 1988-01-05 Webster John A Jr Method for identifying and characterizing organisms
US5574027A (en) * 1989-11-22 1996-11-12 Bernstein; Lawrence R. Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US5258376A (en) * 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US6004951A (en) * 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
DE69225484T2 (de) * 1991-07-25 1998-12-10 Philippe Collery Gallium iii komplexe, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten
JP3348849B2 (ja) * 1991-11-12 2002-11-20 ローレンス リチャード バーンスタイン ３−ヒドロキシ−４−ピロンのガリウム錯体の医薬組成物
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
US6203822B1 (en) * 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections

Also Published As

Publication number Publication date
CA2386325A1 (en) 2001-04-12
WO2001024799A1 (en) 2001-04-12
JP2003510362A (ja) 2003-03-18
DE60032915D1 (de) 2007-02-22
EP1218011B1 (en) 2007-01-10
AU775459B2 (en) 2004-08-05
DE60032915T2 (de) 2007-10-25
KR20020041451A (ko) 2002-06-01
EP1218011A4 (en) 2004-08-18
US20060222628A1 (en) 2006-10-05
EP1218011A1 (en) 2002-07-03
US20030083308A1 (en) 2003-05-01
AU1197601A (en) 2001-05-10
ES2280259T3 (es) 2007-09-16
CA2386325C (en) 2010-08-03

Similar Documents

Publication Publication Date Title
MXPA02003463A (es) Complejos de galio de 3-hidroxi-4-pironas para tratar la infeccion por procariontes intracelulares, virus de adn y retrovirus.
Morahan et al. Immunomodulator-lnduced Resistance Against Herpes Simplex Virus
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
TW371628B (en) Composition for treating condyloma acuminata
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
BR9710355A (pt) Composição útil para o tratamento de infecções virais em um mamìfero, processo para tratar uma infecção viral em um mamìfero, e, produto medicinal.
WO1996010412B1 (en) Use of human chorionic gonadotropin as an immune-potentiating agent
Norrby et al. Treatment of toxoplasmosis with trimethoprim-sulphamethoxazole
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
BR0016163A (pt) Tratamento de infecções virais que usa levovirin(r)
WO2003061602A3 (en) Combination therapy for treatment of hiv infection
ES2148234T3 (es) Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
HK1040064A1 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
Flexner Post-exposure prophylaxis revisited: new CDC guidelines. Centers for Disease Control and Prevention
薛伯寿 Treatment of aids with traditional chinese medicine
EP0642793A4 (en) Apoptosis inducer.
BR0008269A (pt) Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv
EP1731155A3 (en) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
BR9106772A (pt) Processo para tratar e evitar a infeccao por virus da imunodeficiencia humana em individuos mamiferos,incluindo o homem,dispositivo atomizador,composicoes para aplicacoes topica,administracao gastrointestinal,parenteral,transdermica,para revestir equipamento medico,revestimento polimerico e peptideos
James Adefovir dipivoxil (Preveon) new results with hepatitis B, HIV
Bowers Cidofovir
MacDougall Thunderbolts charge the 36th annual IDSA meeting
WO2001030325A3 (en) Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection
James Neuropathy: nutritional prevention/treatment suggested

Legal Events

Date Code Title Description
FG Grant or registration